Gerald L. Denardo
#161,683
Most Influential Person Now
Gerald L. Denardo's AcademicInfluence.com Rankings
Gerald L. Denardobiology Degrees
Biology
#12850
World Rank
#16354
Historical Rank
Cell Biology
#701
World Rank
#715
Historical Rank
Molecular Biology
#2118
World Rank
#2150
Historical Rank
Biochemistry
#2222
World Rank
#2368
Historical Rank
Download Badge
Biology
Why Is Gerald L. Denardo Influential?
(Suggest an Edit or Addition)Gerald L. Denardo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts (2002) (203)
- Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. (1998) (191)
- Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy (2005) (187)
- Application of High Amplitude Alternating Magnetic Fields for Heat Induction of Nanoparticles Localized in Cancer (2005) (172)
- Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. (1990) (153)
- Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice. (2007) (147)
- Radioimmunotherapy: recent results and future directions. (1996) (138)
- Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. (1990) (130)
- Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies (1988) (125)
- Rationales, evidence, and design considerations for fractionated radioimmunotherapy (2002) (120)
- Comparative serum stability of radiochelates for antibody radiopharmaceuticals. (1987) (116)
- Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. (1997) (116)
- Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. (1972) (113)
- A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. (2004) (112)
- Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. (1988) (110)
- Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. (1998) (106)
- NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. (2008) (103)
- Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. (1995) (103)
- Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. (2002) (102)
- Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. (1988) (98)
- The ventilatory lung scan in the diagnosis of pulmonary embolism. (1970) (95)
- Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. (1994) (92)
- Clinical assessment of left ventricular regional contraction patterns and ejection fraction by high-resolution gated scintigraphy. (1975) (92)
- Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies (1987) (88)
- Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. (1997) (88)
- Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma (2007) (84)
- A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. (1999) (83)
- New approach to interpretation of technetium-99m pyrophosphate scintigraphy in detection of acute myocardial infarction: clinical assessment of diagnostic accuracy. (1977) (81)
- Noninvasive measurement of pulmonary transvascular protein flux in normal man. (1980) (81)
- 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. (1999) (75)
- High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody (2005) (73)
- Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. (1999) (73)
- Trials and tribulations: oncological antibody imaging comes to the fore. (1997) (73)
- Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. (2005) (72)
- Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. (1997) (71)
- 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. (1999) (71)
- Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 (2002) (69)
- Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. (1998) (68)
- Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. (1997) (67)
- A new era for radiolabeled antibodies in cancer? (1999) (65)
- Targeted radionuclide therapy. (2008) (65)
- Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. (2004) (65)
- A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates (1994) (63)
- Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. (2008) (61)
- Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. (1995) (61)
- Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. (2000) (61)
- The biologic window for chimeric l6 radioimmunotherapy (1994) (60)
- Requirements for a treatment planning system for radioimmunotherapy. (1985) (59)
- Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. (1998) (59)
- Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10 (1996) (58)
- Human antiglobulin response to foreign antibodies: therapeutic benefit? (2003) (57)
- Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. (1999) (57)
- Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. (1994) (57)
- Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3) (1994) (56)
- Scintigraphy in the diagnosis of osteonecrosis. (1978) (55)
- Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice (2008) (55)
- Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. (1990) (53)
- Targeted radionuclide therapy for solid tumors: an overview. (2006) (53)
- Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. (2003) (52)
- Effect of lym‐1 radioimmunoconjugate on refractory chronic lymphocytic leukemia (1994) (51)
- Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). (1997) (50)
- Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer (2001) (50)
- Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. (1995) (48)
- Evaluation of the liver and spleen in Hodgkin's disease. II. The value of splenic scintigraphy. (1972) (48)
- Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. (1986) (47)
- Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors. (1992) (46)
- A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. (1996) (46)
- Antibody responses to macrocycles in lymphoma. (1996) (46)
- Serum stability of 67Cu chelates: comparison with 111In and 57Co. (1986) (45)
- Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. (1997) (45)
- Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition. (2007) (45)
- 85 Sr bone scan in neoplastic disease. (1972) (44)
- Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand (2004) (44)
- Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. (1986) (43)
- Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies. (1993) (43)
- Update: Turning the heat on cancer. (2008) (43)
- Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131 i‐lym‐1 as a model (1994) (43)
- Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (1999) (43)
- Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. (2001) (42)
- Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma (2013) (42)
- Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. (1998) (42)
- Comparison of low- and medium-energy collimators for SPECT imaging with iodine-123-labeled antibodies. (1986) (41)
- Combined modality radioimmunotherapy (2002) (41)
- The 85-Sr scintiscan in bone disease. (1966) (41)
- Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. (1993) (39)
- Concepts, consequences, and implications of theranosis. (2012) (39)
- Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. (1999) (38)
- Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. (2001) (38)
- Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. (1996) (38)
- Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. (2006) (37)
- Evaluation of the liver and spleen in Hodgkin's disease. I. The value of hepatic scintigraphy. (1972) (37)
- Diagnosis of cirrhosis and hepatitis by quantitative hepatic and other reticuloendothelial clearance rates. (1976) (37)
- Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients (1988) (37)
- A revolution in the treatment of non-Hodgkin's lymphoma. (1998) (37)
- Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system (2004) (37)
- Prevention of lower extremity venous thrombosis by early mobilization. Confirmation in patients with acute myocardial infarction by 125I-fibrinogen uptake and venography. (1976) (36)
- Detection of bone lesions with the strontium-85 scintiscan. (1966) (36)
- A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. (2000) (36)
- Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. (2004) (36)
- Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. (1991) (36)
- Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). (2005) (35)
- Radioimmunotherapy for Breast Cancer: Treatment of a Patient with I-131 L6 Chimeric Monoclonal Antibody (1991) (35)
- Milestones in the development of Lym-1 therapy. (1999) (34)
- Production of carrier-free 123 I using the 127 I(p,5n) 123 Xe reaction. (1972) (34)
- Breast cancer imaging with In-111 human IgM monoclonal antibodies: preliminary studies. (1988) (34)
- Comparison of three boundary detection methods for SPECT using Compton scattered photons. (1988) (33)
- Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. (2003) (33)
- Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. (2000) (33)
- Immunoadsorption: an enhancement strategy for radioimmunotherapy. (1993) (32)
- 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. (1999) (32)
- Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. (1989) (32)
- Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. (1997) (32)
- Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. (2000) (32)
- Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia (2007) (31)
- Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1) (1985) (31)
- Radioimmunotherapy of lymphoma: a UC Davis experience. (1995) (31)
- Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. (2001) (30)
- Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. (2006) (30)
- Imaging for improved prediction of myelotoxicity after radioimmunotherapy (1997) (30)
- Cure of incurable lymphoma. (2006) (30)
- Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. (2007) (29)
- A treatment planning program for radioimmunotherapy. (1989) (29)
- Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. (1998) (29)
- Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. (1998) (28)
- Sodium flux in myotonic muscular dystrophy. (1968) (28)
- Critical Lym-1 binding residues on polymorphic HLA-DR molecules. (1999) (28)
- Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma (1997) (28)
- Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer (2005) (27)
- Assessment of circulation in the femoral head by 18F scintigraphy. (1974) (27)
- Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. (1998) (27)
- Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. (1988) (27)
- Hepatic scintiangiographic patterns. (1974) (26)
- Strategies for developing effective radioimmunotherapy for solid tumors. (1999) (26)
- Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. (2004) (26)
- L6 monoclonal antibody binds prostate cancer (1998) (26)
- Reproducibility of operator processing for radiation dosimetry. (1997) (25)
- Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. (2006) (25)
- Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. (1976) (25)
- Vascularity of the femoral head: 18fluorine scintigraphy validated with tetracycline labeling. (1975) (25)
- Excitation functions and yields for 123I production using the 127I(p, 5n) 123Xe reaction (1975) (25)
- Iodine-123-fibrinogen scintigraphy. (1977) (25)
- Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer. (1999) (25)
- Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. (1996) (24)
- Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies (2005) (23)
- Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy. (2003) (23)
- Pulmonary function studied with the xenon-133 scanning technique. Normal values and a postural study. (1966) (23)
- Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. (1995) (22)
- Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. (2002) (22)
- New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. (1998) (22)
- Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. (2005) (21)
- Radioisotope skeletal survey. (1967) (21)
- Strategies for enhancement of radioimmunotherapy. (1991) (21)
- Radiometals as Payloads for Radioimmunotherapy for Lymphoma Lymphoma (2004) (21)
- Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice. (1977) (20)
- Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. (1998) (19)
- Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody (1992) (19)
- Technetium-99m pyridoxylideneglutamate (P.G.) cholescintigraphy. (1976) (19)
- Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. (2003) (19)
- Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. (2003) (19)
- Development of tissue plasminogen activator specific "on demand cleavable" (odc) linkers for radioimmunotherapy by screening one-bead-one-compound combinatorial peptide libraries. (2007) (19)
- Effect of different linkages between chelates and monoclonal antibodies on levels of radioactivity in the liver. (1989) (19)
- Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. (2001) (19)
- Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. (2003) (18)
- Comparison of oncophilic radiopharmaceuticals, *I‐fibrinogen, 67Ga‐ citrate, 111In‐bleomycin, and *I‐bleomycin in tumor‐bearing mice (1977) (18)
- 31P Surface‐Coil NMR Analysis of Metabolic Status in KHJJ Tumors (1985) (18)
- Quantification of iodine-131 in tumors using a threshold based on image contrast (1998) (17)
- Bronchoscopic location of bronchopleural fistula with xenon-133. (1982) (17)
- Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. (2007) (17)
- Treatment planning for molecular targeted radionuclide therapy. (2002) (17)
- Thallium-201 stress myocardial scintigraphy: Application in asymptomatic patients with positive exercise electrocardiograms (1978) (17)
- Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. (1994) (17)
- Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. (2007) (16)
- Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. (1999) (16)
- Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. (1995) (16)
- Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? (2008) (15)
- Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients. (2004) (15)
- Radiation treatment of B cell malignancies with immunoconjugate. (1990) (15)
- Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. (2006) (15)
- Preparation and chemical characterization of radioiodinated bleomycin. (1975) (15)
- Radioisotope ventriculography in the Arnold-Chiari malformation. (1969) (15)
- Localization of strontium 85 in soft tissue infected by Aspergillus niger. (1971) (15)
- Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. (1999) (15)
- Development of Tumor Targeting Magnetic Nanoparticles for Cancer Therapy (2006) (14)
- Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. (2003) (14)
- Quo vadis radioimmune imaging? (1990) (14)
- 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. (2000) (14)
- Critical evaluation of hepatic scintiangiography for neoplastic tumors of the liver. (1975) (14)
- Cerebrospinal fluid scanning and ventricular shunts. (1970) (14)
- Immediate renal imaging and renography with 99mTc methylene diphosphonate to assess renal blood flow, excretory function, and anatomy. (1980) (14)
- The diagnostic value of brain scanning in intracranial lymphomas. (1972) (14)
- Fluoride-18 scintigraphy in avascular necrotic disorders of bone. (1975) (14)
- Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells. (2008) (14)
- Early diagnosis of venous thrombosis using 125I-fibrinogen. (1977) (13)
- Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers? (2005) (13)
- Scintiscanning in malignant lymphomatous involvement of bone. (1968) (13)
- Determination of improved myocardial perfusion after aortocoronary bypass surgery by exercise rubidium-81 scintigraphy. (1976) (13)
- Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. (2008) (13)
- Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. (2003) (12)
- Radiolabelled monoclonal antibodies for the detection of cancer. (1986) (12)
- Pharmacokinetics of radioiodinated streptokinase. (1975) (12)
- Determination of spleen size by scintigraphy. (1999) (11)
- Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines (2007) (11)
- Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. (2009) (11)
- Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma (1997) (11)
- Radioimmunotherapy with I-131 Chimeric L-6 in Advanced Breast Cancer (1991) (11)
- Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance. (1985) (11)
- Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. (1994) (10)
- Bone pain palliation. (1998) (10)
- Characterization of human IgG antimouse antibody in patients with B-cell malignancies. (2003) (10)
- Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody. (2005) (10)
- Enhancement of clinical radioimmunotherapy for cancer and the role of cytokines. (1992) (10)
- Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphoma. (2003) (10)
- Practical determination of organ S values for individual patients for therapy. (1997) (10)
- A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy. (1998) (10)
- Problem of diffuse cardiac uptake of technetium-99m pyrophosphate in the diagnosis of acute myocardial infarction: enhanced scintigraphic accuracy by computerized selective blood pool subtraction. (1977) (9)
- Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model. (1999) (9)
- Origin and evolution of radioactive pulmonary emboli in man. (1968) (9)
- Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer (1992) (9)
- Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm. (2010) (9)
- Prediction of myelotoxicity using semi-quantitative marrow image scores. (1997) (9)
- Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. (2005) (8)
- Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells (2009) (8)
- CLINICAL APPLICATION OF BONE SCINTISCANS. (1968) (8)
- Review of a 5-year experience with the radiostrontium bone scintiscan. (1972) (8)
- Editorial Bone Pain Palliation (1998) (8)
- Pharmaceutical quality control of radiolabeled monoclonal antibodies and their fragments. (1989) (8)
- Abnormal peripheral distribution of Thallium-201 due to arteriosclerosis. (1978) (8)
- Experience with 99mTc diphosphonate in studying vascularity of the femoral head. (1975) (8)
- 67 Cu- versus 131 I-Labeled Lym-1 Antibody: Comparative Pharmacokinetics and Dosimetry in Patients with Non-Hodgkin’s Lymphoma 1 (1999) (8)
- Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival? (2003) (7)
- Radiometals as payloads for radioimmunotherapy for lymphoma. (2004) (7)
- I-fibrinogen as an oncophilic radiodiagnostic agent: distribution kinetics in tumour-bearing mice. (1977) (7)
- Lung scans with I-131 labelled macroaggregated human serum albumin (maa). (1966) (7)
- 123I radiolabeling of monoclonal antibodies for in vivo procedures. (1986) (7)
- The conundrum of personalized cancer management, drug development, and economics. (2007) (7)
- Evaluation of myocardial uptake of 99mtechnetium pyrophosphate in clinical exercise-induced ventricular ischemia. (1977) (7)
- Comparison of I-bleomycin prepared by two methods stability and pharmacokinetics in tumor-bearing mice. (1977) (6)
- Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial. (2004) (6)
- On the analysis of count data of birth‐and‐death process type: with application to molecularly targeted cancer therapy (2007) (6)
- Catabolism and protein binding of Tc-99m pyridoxylideneglutamate. (1978) (6)
- Acute intermittent porphyria associated with hyperthyroidism. (1965) (6)
- Accuracy of noninvasively determined left ventricular volumes by gated radionuclide cineangiography in coronary, valvular and myocardial heart diseases (1978) (6)
- Planar gamma camera quantitation of 123I, 99mTc or 111In in the liver and spleen of an abdominal phantom. (1999) (6)
- Assessment of conventional criteria for the early diagnosis of thrombophlebitis with the 125I-fibrinogen uptake test. (1977) (6)
- Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage. (1999) (5)
- LYM-1 radioimmunotherapy : a case history of how we do it (1992) (5)
- Enhanced scintigraphic information display using computer-generated ratio techniques. (1970) (5)
- Review of a four-year experience iodinating monoclonal antibodies with therapeutic amounts of I-131 (1995) (5)
- Biology of radionuclide therapy (1989) (5)
- Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth. (1997) (5)
- Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy (1996) (5)
- THE PREOPERATIVE DIAGNOSIS OF SPLEEN CYSTS BY SCINTISCANNING. REPORT OF A CASE. (1965) (5)
- Production and characteristics of 81Rb for myocardial studies. (1978) (5)
- Thrombosis Detection: Fibrinogen Counting and Radionuclide Venography (1981) (5)
- Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. (1996) (5)
- 123I fibrinogen imaging of thrombi in dogs (1974) (5)
- When is too much too much and yet not enough? Alas, a plethora of opportunities but where's the beef? (2000) (5)
- Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator. (1996) (5)
- Production and characteristics of 125Xe: a new noble gas for in vivo studies. (1975) (5)
- Rapid PCR construction of a gene containing Lym-1 antibody variable regions. (1993) (5)
- Radiolabeled anti-lymphoma antibodies. (2001) (5)
- Use of the linear-quadratic model to compare doses delivered to the bone marrow by 131-I-Lym-1 radioimmunotherapy (1995) (5)
- Thyroid function and enovid. (1966) (5)
- Detection of thrombophlebitis in the lower extremities: a regional comparison of 123I fibrinogen scintigraphy and contrast venography. (1985) (5)
- Radioactive labeling of protein carboxyl groups on factor VIII: use of carbodiimides for nuclear medicine. (1977) (4)
- Metabolite production in patients with lymphoma after radiometal-labeled antibody administration. (2001) (4)
- Dynamic studies with radioisotopes. (1967) (4)
- Efficient recombination of Lym-1 scFv gene using multiple doubly-restricted DNA fragments. (1999) (4)
- Antibody phage display applications for nuclear medicine imaging and therapy. (2000) (4)
- Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. (1999) (4)
- Editorial: "right place, wrong place": extravasation of therapeutic drug for molecular targeted radiotherapy. (2006) (4)
- Hereditary spherocytosis and infectious mononucleosis, with acquired hemolytic anemia. Report of a case and review of the literature. (1963) (4)
- The Design of a Radiolabeled Monoclonal Antibody for Radioimmunodiagnosis and Radioimmunotherapy (1988) (4)
- Rubidium 81 imaging at rest and after exercise: Screening test for myocardial ischemia (1974) (4)
- Radiopharmaceutical preparation of a monoclonal antibody, lym‐1, and its F(ab')2 fragment for imaging lymphoma with In‐111 (1989) (4)
- Editorial: 2008: State of Affairs for Cancer Biotherapy & Radiopharmaceuticals (2008) (4)
- EFFECTS OF PROTEIN MASS ON THE PHARMACOKINETICS OF MONOCLONAL ANTIBODIES (MoAb) (1984) (3)
- Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy. (1999) (3)
- RADIOIMMUNOTHERAPY FOR BREAST CANCER USING ESCALATING FRACTIONATED DOSES OF 1–131 CHIMERIC (Ch) L6 (1994) (3)
- Practical simplifications for radioimmunotherapy dosimetric models (1999) (3)
- A new constant infusion radioisotopic technique for the noninvasive determination of cardiac output. (1976) (3)
- Studies of nutrient blood flow of the dog liver as measured by 133xenon. (1970) (3)
- Coccidioidomycosis complicating Hodgkin's disease, with a note on furaltadone-induced neuropathy. (1962) (3)
- MINERVA: a multi-modality plugin-based radiation therapy treatment planning system. (2005) (3)
- Targeted radionuclide therapy. (2008) (2)
- The role of hepatic scintiangiography in patients with liver disease (1976) (2)
- Treatment of cancer with intratumoral infusion of radioisotopes. (1994) (2)
- Isotope imaging in the diagnosis of primary and secondary tumors of the liver. (1978) (2)
- PERIFUSIONAL TECHNIQUES FOR SCREENING ANTIBODIES (Ab) IN LIVING TISSUE.: I3 (1983) (2)
- Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules. (2007) (2)
- Comparison of the pulmonary distribution of xenon-133 solution and iodine-131 macroaggregated albumin. (1967) (2)
- Development of antibody directed nanoparticles for cancer therapy (2007) (2)
- Cerebrospinal-fluid dynamics. (1970) (2)
- RADIOIMMUNOTHERAPY IN BREAST CANCER: CURRENT RESULTS IN PHASE I PROTOCOLS (1992) (2)
- Dosimetry for radioimmunotherapy: a rapidly evolving field. (1999) (2)
- Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy. (2008) (2)
- Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. (2007) (2)
- Effects of changes of canine portal vein flow on hepatic artery hemodynamics. (1972) (2)
- New directions in radioimmunotherapy of non-Hodgkin's lymphoma. (2004) (2)
- Comparison of rubidium 81 and thallium 201 rest and exercise myocardial scintigraphy in the noninvasive detection of regional myocardial ischemia (1977) (2)
- Cancer Treatment with Radioactive Labeled Antibodies (1986) (2)
- Regional distribution of feline esophageal blood flow. (1971) (2)
- Tumor localization in animals and patients using radioiodinated bleomycin (1975) (2)
- Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. (2006) (2)
- Scintigraphic imaging of a blind-ending ureteral duplication. (1975) (2)
- Development of pure, homogeneous monoclonal antibody fragments as a resource for radiopharmaceuticals (1982) (2)
- Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues. (2007) (1)
- Exercise Renography in Untreated Subjects with Essential Hypertension (1996) (1)
- 18-F scintigraphy in diagnosis and management of avascular necrosis bone disorders. (1973) (1)
- Human IgG responses to macrocyclic chelating agents (DOTA and TETA) in patients with B-lymphocytic malignancies (1995) (1)
- Molecular imaging/therapy: it's only useful if it's useful--and available. (2008) (1)
- Novel nanomolecular HLA-DR10 antibody mimics provide a potent system for molecular therapy and imaging (2008) (1)
- IN VIVO MONITORING OF RIT IN LYMPHOMA BY QUANTITATION OF PHOSPATE METABOLITES WITH 31P‐NMR (1984) (1)
- S16 03 TA – RADIOIMMUNOTHERAPY STUDIES IN BREAST CANCER AND LYMPHOMA (1991) (1)
- Effect of the extent of substitution on the immunoreactivity of 21T-BAT-LYM-1 immunoconjugate (1994) (1)
- Evaluation of myocardial uptake of /sup 99m/Tc pyrophosphate in clinical exercise-induced ventricular ischemia (1977) (1)
- Noninvasive radioisotopic evaluation of regional dyskinesis and pump performance in coronary disease: Use of nitroglycerin in detection of reversible segmental ischemia (1974) (1)
- Distribution of blood flow to the muscle and mucosa of the rat esophagus. (1971) (1)
- Clinical assessment of Tc 99m pyrophosphate scintigraphy in exercise induced transient myocardial ischemia (1975) (1)
- Radioimmunotherapy with Monoclonal Antibodies (1990) (1)
- Clinical usefulness of I123 fibrinogen (I123 F) for detection of thrombophlebitis (TP) (1975) (1)
- Chloramine-T radioiodination of monoclonal antibodies with NaI-123 (p,5n) (1984) (1)
- Quantitative pharmacokinetics of radiolabled monoclonal antibodies in patients (1986) (1)
- Rapid placental imaging and localization utilizing ionic technetium-99m pertechnetate. (1967) (1)
- Clinical safety of fibrinogen I 125 (Human) injection from screened individual donors (1975) (1)
- The design of a radiolabeled monoclonal antibody for radioimmunotherapy (1986) (1)
- Clinical trial of I-123-bleomycin for tumor detection (1978) (1)
- Monoclonal antibodies in imaging (1989) (1)
- Radioimmunoassay of fibrinopeptide A in patients with cancer (1978) (1)
- Ligands polyvalents selectifs a haute affinite et methodes de fabrication (2005) (0)
- Pre-clinical development of a 188Re-labeled melanin-binding antibody for phase I clinical trial in patients with metastatic melanoma (2008) (0)
- Nuclear medicine-epitomes of progress: iodine 125 fibrinogen uptake test. (1978) (0)
- UPTAKE OF FIBRIN MONOCLONAL ANTIBODY (MAb) BY A MOUSE CANCER WITH COAGULATIVE PROPERTIES.: C8 (1986) (0)
- The future of radioiodines (1983) (0)
- VALIDITY OF PREDICTION OF RADIATION DOSE TO WHOLE BODY, ORGANS AND TUMORS FROM TRACER PHARMACOKINETIC STUDIES WITH 1–131 (1994) (0)
- SPLENIC VOLUME CHANGE AND THERAPUETIC RESPONSE IN PATIENTS TREATED WITH RADIOMMUNOCONJUGATES (2005) (0)
- MINERVA: A multimodality plugin-based radiation therapy treatment planning system (2004) (0)
- Clinical study of Tc-99m pyrophosphate scintigraphy in exercise-induced ventricular ischemia: Validation of technetium pyrophosphate specificity in myocardial infarction (1976) (0)
- Rest and exercise myocardial imaging with Rb 81 and the scintillation camera: improved screening for significant coronary stenosis (1975) (0)
- A thrilling ride (2011) (0)
- jDIII/DIAGNOSTIC NUCLEAR MEDICINE Diagnosis of Cirrhosis and Hepatitis by Quantitative Hepatic and Other ReticuIoendotheiiai Clearance Rates (2006) (0)
- Preparation and chemical characterization of I bleomycin (1975) (0)
- Cassen Award (created in 1994 - awarded every other year) Education and Research Foundation (2012) (0)
- Health care in the United States in 2009: both sides of the "counter". (2009) (0)
- STABILITY OF RADIOIODIMATED MONOCLONAL ANTIBODIES (MoAb) AND THEIR F(ab')2 AND Fab FRAGMENTS IN VITRO (1984) (0)
- Abstract 2703: Effect of route and dosing regimen on efficacy of SH7139 in mouse Burkitt's lymphoma xenografts (2014) (0)
- 'Historical vignettes': Editorial (1999) (0)
- Multicompartmental Analysisof the Kinetics of RadioiodinatedMonoclonalAntibody in Patientswith Cancer (1986) (0)
- Tribute to ralph A. Reisfeld, ph.D. (1997) (0)
- Hepatic scintiangiography in malignant parasitic tumors. (1974) (0)
- Biotherapy of cancer marches on! (1998) (0)
- Radioimmunodetection of Prostatic Carcinoma: Assessment of Extent of Disease (1987) (0)
- Development of xenon 125 for in vivo studies (1974) (0)
- Direct noninvasive evaluation of mechanism of action of cardioselective beta blocking agents in patients with angina pectoris using exercise rubidium 81 myocardial imaging (1976) (0)
- Past, present and future of radioiodines in medicine (1982) (0)
- Iodine 125 Fibrinogen Uptake Test (2005) (0)
- in Breast Cancer Xenografts with Radioimmunotherapy to Increase Efficacy and Apoptosis Integrin Receptor Synergizes (2002) (0)
- P-31-NMR analysis of in vivo metabolic events in lymphoma during RIT (1985) (0)
- Efficacy and toxicity of 90Y-DOTA-biotin after pretargeted intratumoral avidin in mice implanted with human breast cancer (HBT 3477) (2006) (0)
- Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT). (2010) (0)
- Radioimmunotherapy : A New Treatment Modality for B-Cell Non-Hodgkin ’ s Lymphoma (2017) (0)
- Comparison of rubidium 81 and technetium 99m pyrophosphate sensitivity in the diagnosis of exercise induced ischemia - usefulness of Tc 99m pyrophosphate in the acute myocardial infarction (1976) (0)
- Effect of chloramine-T labeling conditions on the stability of monoclonal antibodies and their fragments (1985) (0)
- Animal studies with Se75-selenomethionine. (1967) (0)
- About the old and the new: gallium-67 scintigraphy to rituximab for lymphoma. (1999) (0)
- Treatment of B-Lymphocyte Malignancies with 131l-Lym-1 and 67Cu-2IT-BAT-Lym-1 and opportunities for improvement (2018) (0)
- Angina with normal coronary arteriograms: analysis of regional myocardial perfusion by rest and exercise rubidium 81 scintigraphy (1977) (0)
- Effect of Mass of ' "In-Benzyl-EDTA Monoclonal Antibody on Hepatic Uptake and Processing in Mice1 (2006) (0)
- acid (DOTA)-.Peptide-ChL6, a Novel linmunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2- (p-(Bromoacetamido)benzyl)-DOTA-ChL6 in Breast Cancer Xenografts' (1998) (0)
- The use of I 125 fibrinogen in the diagnosis of deep vein thromboses (1974) (0)
- YTTRIUM-90 CHIMERIC L6 THERAPY IN NUDE MICE WITH HUMAN BREAST TUMORS: APOPTOSIS ASSOCIATED mRNAs IN RESPONDING HUMAN BREAST TUMORS (1994) (0)
- Cyclotron production of carrier-free 123 I using the reaction 127 I (p, 5n) 123 Xe. (1972) (0)
- BronchoscopicLocationof BronchopleuralFistulawith Xenon-133 (2006) (0)
- A modified post processing attenuation correction method for SPECT (1985) (0)
- Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft. (2005) (0)
- Abstract 5460: Intracellular uptake and metabolism of SH7139: Is it a targeted prodrug for B-cell lymphomas (2014) (0)
- QUANTITATION OF TUMOR UPTAKE OF IODINE-131 USING A CONTRAST DEPENDENT THRESHOLD TECHNIQUE (1994) (0)
- Year 2001: An Even Better Year for CB&R (2001) (0)
- Letter: "Polyphosphate bone scans, 32phosphorus, and adenocarcinoma of the thyroid". (1975) (0)
- Dosimetric evaluation for radioimmunotherapy of Cu-64-2IT-BAT-LYM-1 radiocontaminant in Cu-67-2IT-BAT-LYM-1 radiopharmaceutical (1994) (0)
- Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients withMetastatic Melanoma (2013) (0)
- Changes Occur But Often Little Really Changes (2009) (0)
- QUANTITATIVE MoAb RADIOIMMUNOTHERAPY IMAGING WITH MIRDOSE2 DOSIMETRY (1992) (0)
- Year 2002: the best year yet for CB&R. (2002) (0)
- Direct determination of myocardial perfusion pattern before and after aortocoronary bypass by non invasive rest and exercise rubidium 81 scintigraphy (1975) (0)
- Quantification of factors determining thallium 201 myocardial uptake with exercise stress testing: Evidence that radionuclide image is related to heart rate as well as to coronary disease (1979) (0)
- Banner Millennium 2000 Year for CB&R and Mary Ann Liebert (2000) (0)
- Tumor Imaging: Current State of the Art and Recommendations for Future Research D. G. Bragg, W. R. Hendee, Eds. Norwalk, CT, Appleton-Century-Crofts, 1982, 150 pp, $18.95 (1983) (0)
- Today and tomorrow: radiochemistry for radioimmunotherapy of breast cancer. (1990) (0)
- RADIOIODINATED STREPTOKINASE (2006) (0)
- RADIOIMMUNOTHERAPY STUDIES IN BREAST CANCER (1992) (0)
- Memorial and Eulogy Ralph J. Gorten, M.D. 1927-1997 (1998) (0)
- Concentration in Blood and Body Practical Determination of Patient-Specific Marrow Dose Using Radioactivity (2006) (0)
- 111In-DOTA-biotin pharmacokinetics after pretargeted intratumoral avidin in a human breast cancer mouse model (2006) (0)
- Vascularity of the femoral head: $sup 18$F scintigraphy validated with tetracycline labeling (1975) (0)
- Pharmacokinetics of Chimeric Ui Conjugated to Indium-ill-and Yttrium.90-DOTA-Peptide in Tumor-Bearing Mice (2006) (0)
- Ligands polydentes a haute affinite selective et procedes de fabrication de tels ligands (2009) (0)
- Bronchoscopic location of bronchopleural fistula with /sup 133/Xe (1982) (0)
- P19 13 MP – QUANTITATION OF HAMA IN CANCER PATIENTS (1991) (0)
- Tumor targeting anti-MUC1 Di-scFv: Effects of free cysteine location on PEGylation and tumor binding (2006) (0)
- "Historical Vignettes". (1999) (0)
- Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy 1 (2003) (0)
- Characterization of nanomolecular-size mimics for HLA-DR antibody, Lym-1, to image and treat lymphoma and leukemia (2007) (0)
- Tcchnctium in Chemistry and Nuclear Medicine (1986) (0)
- Confronting the problem of Cu-67 radiation measurement in the presence of contaminating Cu-64 isotope, using simple nuclear medicine radioisotope dose calibrator (1994) (0)
- Overview of Obstacles and Opportunities for Radioimmunotherapy of Cancer (2018) (0)
- Use of response surface statistical designs to detect effects of biologic response modifiers such as IL-2. (1994) (0)
- Enhancement of theTherapeutic Index : FromNonmyeloablative andMyeloablative toward Pretargeted Radioimmunotherapy forMetastatic Prostate Cancer (2005) (0)
- Diagnosis of pulmonary embolism. (1970) (0)
- Tribute to David A. Goodwin and Claude F. Meares, recipients of the Immunomedics Science Award. (1999) (0)
- Biology of radionuclide therapy. Proceedings (1989) (0)
- Reproducibility of radiation dosimetry assessed in a phantom and in 20 patients by planar imaging studies (1995) (0)
- Application of Monte Carlo Methods in Molecular Targeted Radionuclide Therapy (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gerald L. Denardo?
Gerald L. Denardo is affiliated with the following schools:
